👉BSEM is TODAY’S #1 ALERT*

Hey Folks, Jeff Bishop here.

Even with the markets very mixed lately, I’ve had awesome success identifying “tactical trade” ideas that went on to surge double digits the day I alerted them.

I think today is the perfect time to revisit a stock that has had some amazing runups over the last few years…

It’s very rare that I point to an OTC idea, but this is one of the very few OTC stocks worth looking at.

💥Go ahead and pull up BioStem Technologies, Inc. (BSEM) on your favorite trading platform.

When I alerted this stock in January, it climbed a respectable 10% intraday, but that was only the beginning…

Over the next six trading days, it steadily climbed as high as 39% from its closing price before my alert.

The stock ripped from mid-November through the end of the month into late November, gaining as much as 61% at one point.

It pulled back into mid-December, but last Tuesday, it began another rally, and it’s now up 19% from its low that day.

With that momentum at its back, this is my 👉#1 ALERT*👈  for the day so be sure to keep it at the very top of your radar!

Once you look into the company, I think you’ll be very impressed.

Not to bury the lede, the company posted some astonishing gains on its financials earlier this year…

On April 14, it announced record preliminary net revenue for Q4 2024 of $102.9 million and full-year 2024 net revenue of $301.8 million.

These numbers marked year-over-year improvements of 790% and 1,700%, respectively.

Then on May 12, it reported preliminary Q1 2025 net revenue of $72.5 million, up 73% compared to Q1 2024.

On November 13, BSEM touted Q3 2025 net income of $0.8 million, marking its “seventh consecutive quarter of positive adjusted EBITDA.”

👉 But here’s the thing:  Zacks Small Cap Research has been covering BSEM and right now cites a $25.50 12-month price target for it.

That’s 501% upside from its closing price on Friday.

So what exactly is BSEM up to?

The company is a Florida-based commercial-stage company focused on development, manufacture, and commercialization of placental-derived allografts for advanced wound care.

It says it is a “leading regenerative medicine company” and its mission is “to create and deliver the most advanced wound healing technologies in the world.”

It currently has five placental-derived allograft products on the market. An allograft is “tissue recovered from a human donor for transplantation into another person.”

For more than 100 years, doctors have used the human amniotic membrane to help heal wounds. The membranes are rich in “growth factors, extracellular matrix (ECM) components, and cytokines which are known to support the body’s natural healing processes.”

Furthermore, they are seemingly immune-neutral and “disappear and integrate with the patient’s own tissue without a host reaction.”

BSEM’s innovation is its patented BioREtain process which “preserves the integrity of the amniotic tissue factors critical to the healing process.”

The resulting allografts are sterile, can be stored at ambient temperature, and are shelf-stable up to four years.

As of September, the company had recovered 5,000+ placentas and distributed more than 100,000+ allografts.

Retrospective studies — including this one published in the peer-reviewed International Wound Journal in October — have found that BSEM’s allografts:

• Promote faster wound healing times
  
• Require fewer applications
  
• Can reduce healthcare costs
  
• Improve patient outcomes

The company launched a clinical trial in October 2024 to evaluate one of its allograft products “against the standard of care for patients suffering from non-healing diabetic foot ulcers (DFUs).” The company completed enrollment in June of this year. 

And on October 31, it announced “Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers.” Notably, “The probability of healing in the BR-AC arm was 53% while the probability of healing in the standard of care arm was 31%.”

In January, it launched another, similar trial for another one of its allograft products.

DFUs are surprisingly common, with 15% of diabetics developing them at some point, and between 14% and 24% of those who get them will ultimately need an amputation (!).

In February, BSEM received approval for a clinical study to evaluate its proprietary BioREtain®Amnion Chorion (BR-AC) for the treatment of venous leg ulcers.

I strongly recommend doing your own homework on BSEM ASAP. This September 2025 investor presentation is a great place to start as is the company website.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: BSEM began a rally last Tuesday and is now up 19% from its low that day.

It still has plenty of upside, though, even to hit its high from late November.

💥Stay locked into BSEM today to see where it goes from here!

To Your Success,

Jeff Bishop

*ISSUER-SPONSORED DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars cash from BioStem Technologies, Inc (via Sideways Frequency) for advertising BioStem Technologies, Inc for a one day marketing program on December 22, 2025. Prior to this, we received fifteen thousand dollars (cash) from Sideways Frequency for advertising BioStem Technologies, Inc for a one day marketing program on June 9, 2025. Prior to this, we received thirty one thousand five hundred dollars (cash) from Sideways Frequency for advertising BioStem Technologies, Inc for a one day marketing program on January 28, 2025 and we also received ten thousand dollars (cash) from Sideways Frequency for advertising BioStem Technologies, Inc for a one day marketing program on November 18, 2024. To date, we have received seventy one thousand five hundred dollars for advertising BioStem Technologies, Inc.

This was paid by someone else not connected to BioStem Technologies, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into BioStem Technologies, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities br0ker-deale.r, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.